Literature DB >> 805205

Specificity of human lymphocyte complement receptors.

G D Ross, M J Polley.   

Abstract

Erythrocytes, bone marrow-derived lymphocytes, monocytes, and granulocytes were shown to have a receptor activity for C4. Theis C4 receptor activity was studied in relation to the previously identified C3b and C3d receptors. By assay for inhibition of rosette formation by fluid-phase complement (C), only two different lymphocyte C receptors were demonstrated. The immune adherence receptor, the only one of the two shared in common with erythrocytes, was specific for C4 or the C3c region of C3b, but was unreactive with C3d. The other lymphocyte receptor, the C3d receptor, was specific for C3d fragments, but would also react to a lesser extent with the C3d region of uncleaved C3b. ThC3d receptor did not react with either C3c or C4. This specificity of the C3d receptor allowed certain cells which contained only C3d receptors to form rosettes with EAC1-3b and EAC1-3d, but not with EAC14. However, because C3d receptors bound EAC1-3d or C3d fragments more firmly than they did EAC1-3b or C3b fragments, many other types of cells containing only C3d receptors, formed rosettes with EAC1-3d but not with EAC1-3b. Erythrocytes and those lymphocytes which contained only immune adherence receptors, formed rosettes with EAC14 and EAC1-3D but not with EAC1-3d. A double-label assay was devised for the simultaneous detection of both types of C receptors on individual lymphocytes. This assay involved fluorescence labeling of one of the two C receptors with soluble C fragments in combination with the usual rosette method for labeling the other type of C receptor. With this double-label assay, it was observed that the two different lymphocyte C receptors capped independently and thus were located on different molecules which could each move through the fluid membrane matrix independently of the other.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 805205      PMCID: PMC2189795          DOI: 10.1084/jem.141.5.1163

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  25 in total

1.  A STUDY OF MALIGNANT TUMOURS IN NIGERIA BY SHORT-TERM TISSUE CULTURE.

Authors:  J V PULVERTAFT
Journal:  J Clin Pathol       Date:  1965-05       Impact factor: 3.411

2.  The demonstration in human serum of "conglutinogen-activating factor" and its effect on the third component of complement.

Authors:  P J Lachmann; H J Müller-Eberhard
Journal:  J Immunol       Date:  1968-04       Impact factor: 5.422

3.  Complement dependent immune phagocytosis. I. Requirements for C'1, C'4, C'2, C'3.

Authors:  I Gigli; R A Nelson
Journal:  Exp Cell Res       Date:  1968-07       Impact factor: 3.905

4.  Physico-chemical characteristics of the third and fourth component of complement after dissociation from complement-cell complexes.

Authors:  A P Dalmasso; H J Müller-Eberhard
Journal:  Immunology       Date:  1967-09       Impact factor: 7.397

5.  Hemolytic activity of lipoprotein-depleted serum and the effect of certain anions on complement.

Authors:  A P Dalmasso; H J Müller-Eberhard
Journal:  J Immunol       Date:  1966-11       Impact factor: 5.422

6.  The second component of human complement: its isolation, fragmentation by C'1 esterase, and incorporation into C'3 convertase.

Authors:  M J Polley; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1968-09-01       Impact factor: 14.307

7.  ISOLATION OF BETA IF-GLOBULIN FROM HUMAN SERUM AND ITS CHARACTERIZATION AS THE FIFTH COMPONENT OF COMPLEMENT.

Authors:  U R NILSSON; H J MUELLER-EBERHARD
Journal:  J Exp Med       Date:  1965-08-01       Impact factor: 14.307

8.  COMPONENTS OF GUINEA PIG COMPLEMENT. I. SEPARATION OF A SERUM FRACTION ESSENTIAL FOR IMMUNE HEMOLYSIS AND IMMUNE ADHERENCE.

Authors:  K NISHIOKA; W D LINSCOTT
Journal:  J Exp Med       Date:  1963-11-01       Impact factor: 14.307

9.  ISOLATION AND DESCRIPTION OF THE FOURTH COMPONENT OF HUMAN COMPLEMENT.

Authors:  H J MUELLER-EBERHARD; C E BIRO
Journal:  J Exp Med       Date:  1963-09-01       Impact factor: 14.307

10.  Isolation of a fragment (C3a) of the third component of human complement containing anaphylatoxin and chemotactic activity and description of an anaphylatoxin inactivator of human serum.

Authors:  V A Bokisch; H J Müller-Eberhard; C G Cochrane
Journal:  J Exp Med       Date:  1969-05-01       Impact factor: 14.307

View more
  48 in total

1.  Rosette-formation with mouse erythrocytes. II. A marker for human B and non-T lymphocytes.

Authors:  S Gupta; R A Good; F P Siegal
Journal:  Clin Exp Immunol       Date:  1976-08       Impact factor: 4.330

2.  Human lymphocyte complement receptors. Quantitative requirements for C3 of normal and chronic lymphocyte leukemia lymphocytes.

Authors:  G L Logue; H J Cohen
Journal:  J Clin Invest       Date:  1977-11       Impact factor: 14.808

3.  Complement bridges between cells analysis of a possible cell-cell interaction mechanism.

Authors:  M P Dierich; B Landen
Journal:  J Exp Med       Date:  1977-12-01       Impact factor: 14.307

4.  Quantitative influence of antibody and complement coating of red cells on monocyte-mediated cell lysis.

Authors:  R J Kurlander; W F Rosse; G L Logue
Journal:  J Clin Invest       Date:  1978-05       Impact factor: 14.808

5.  Surface marker and other characteristics of Gaucher's cells.

Authors:  G F Burns; J C Cawley; R J Flemans; K E Higgy; C P Worman; C R Barker; B E Roberts; F G Hayhoe
Journal:  J Clin Pathol       Date:  1977-10       Impact factor: 3.411

6.  C3-reacted sepharose: a preparative method for separating T and B lymphocytes.

Authors:  P Casali; B M Perussia
Journal:  Clin Exp Immunol       Date:  1977-01       Impact factor: 4.330

7.  B-cell lymphoma lacking Fc- and C3d-receptors.

Authors:  E Thiel
Journal:  Blut       Date:  1978-12-15

8.  A subpopulation of normal human peripheral B lymphcytes that bind IgE.

Authors:  A Gonzalez-Molina; H L Spiegelberg
Journal:  J Clin Invest       Date:  1977-04       Impact factor: 14.808

9.  Rosette formation with mouse erythrocytes. IV. T, B and third population cells in human tonsils.

Authors:  S Gupta; R Pahwa; F P Siegal; R A Good
Journal:  Clin Exp Immunol       Date:  1977-05       Impact factor: 4.330

10.  C3b inactivator in the rheumatic diseases. Measurement by radial immunodiffusion and by inhibition of formation of properdin pathway C3 convertase.

Authors:  K Whaley; P H Schur; S Ruddy
Journal:  J Clin Invest       Date:  1976-06       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.